Applied Chemical Engineering

Development of HPLC method for isomeric impurities of key starting material of novel oral anticoagulant drug; Edoxaban Tosylate Monohydrate

Vijaya Kumar Baksam

JNTUA university

Saritha Nimmakayala

DOI: https://doi.org/10.59429/ace.v7i2.2326

Keywords: edoxaban starting material; isomeric impurities; development; validation; HPLC

---

Abstract

Reverse-phase high-performance liquid chromatography method has been developed for the determination of EDO-S1 stereoisomeric impurities such as isomer 1, isomer 2, isomer 3, isomer 4, isomer 5, isomer 6 and isomer 7 with good resolution using the column, Bakerbond C18 (150 × 4.6 mm; 3 μm). The separation was achieved with mobile phase-A (10 mM dipotassium hydrogen phosphate pH-7.0 with 10% orthophosphoric acid solution in Milli-Q water) and mobile phase-B (n-Propanol: Acetonitrile ratio of 20:30 % V/V), which consisted of mobile phase mixture in the combination of moilephase-A: mobile phase-B (85:15). The total run time was 30 min at 0.8 mL/min flow rate, 20 µL injection volume and 30 ℃ column oven temperature. The column eluate was monitored at 210 nm to quantify the impurities The method showed adequate specificity, sensitivity, linearity, accuracy, precision, and robustness inline to ICH tripartite guidelines. The limit of detection and quantification limits were 0.1 and 0.3 μg mL⁻¹, respectively, for all isomeric impurities and EDO-S1. The developed method was found to be linear over the concentration range of LOQ to 150% of specification range for isomeric impurities with a correlation coefficient >0.999. The method was precise (%RSD < 5.0), robust, and accurate (with 85%–115% recovery).

---

References

[1]. Tom C, John EF, Matt GH, et al. Study on persistent organic pollutants in Southern Town. Journal of Smart Construction 2013; 1(2): 5–8.

[2]. Rentsch KM. The importance of stereoselective determination of drugs in the clinical laboratory. Journal of Biochemical and Biophysical Methods. 2002, 54(1-3): 1-9. doi: 10.1016/s0165-022x(02)00124-0

[3]. Walther W, Netscher T. Design and development of chiral reagents for the chromatographic e.e. determination of chiral alcohols. Chirality. 1996, 8(5): 397-401. doi: 10.1002/(sici)1520-636x(1996)8:5<397::aid-chir7>3.0.co,2-b

[4]. Katzung B, SusanB, Anthony J. et al. Basic and clinical pharmacology. In: The nature of drugs. New York: Lange Medical Books/McGraw Hill. 2004; p:3–5.

[5]. Lien AN, Hua H, Chuong PH, et al. Chiral drugs: An overview. Int J Biomed Sci 2006; 2: 85-100.

[6]. Simonyi M, Fitos I, Visy J. Chirality of bioactive agents in protein binding storage and transport processes. Trends in Pharmacological Sciences. 1986, 7: 112-116. doi: 10.1016/0165-6147(86)90276-2

[7]. US Food Drug Administration. FDA policy statement for the development of new stereoisomeric drugs, Chirality 1992; 4: 338.

[8]. Rauws AG, Groen K. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Chirality. 1994, 6(2): 72-75. doi: 10.1002/chir.530060206

[9]. Branch SK. Guidelines from the International Conference on Harmonisation (ICH). Journal of Pharmaceutical and Biomedical Analysis. 2005, 38(5): 798-805. doi: 10.1016/j.jpba.2005.02.037

[10]. Zhang T, Nguyen D, Franco P, et al. Cellulose tris(3,5-dichlorophenylcarbamate) immobilised on silica: A novel chiral stationary phase for resolution of enantiomers. Journal of Pharmaceutical and Biomedical Analysis. 2008, 46(5): 882-891. doi: 10.1016/j.jpba.2007.06.008

[11]. Aboul-Enein HY. High-performance liquid chromatographic enantioseparation of drugs containing multiple chiral centers on polysaccharide-type chiral stationary phases. Journal of Chromatography A. 2001, 906(1-2): 185-193. doi: 10.1016/s0021-9673(00)00950-x

[12]. Baksam V, Pocha VR, Chakka VB, et al. Development of an effective novel validated stability‐indicating HPLC method for the resolution of brivaracetam stereoisomeric impurities. Chirality 2020; 32(9): 1208-1219.

[13]. Baksam VK, Saritha N, Mohan SK, et al. Identification and characterization of Prothionamide degradation impurities by mass spectrometry, NMR spectroscopy, and ultra high performance liquid chromatography method development. Journal of Separation Science. 2021, 44(10): 2078-2088. doi: 10.1002/jssc.202100050

[14]. Rognoni C, Marchetti M, Quaglini S, et al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Journal of Thrombosis and Thrombolysis. 2014, 39(2): 149-154. doi: 10.1007/s11239-014-1104-3

[15]. Kalyankar GG, Vansiya PritiH, Bodiwala KB, et al. Development and Validation of Spectrophotometric Method for the Estimation of Edoxaban Tosylate Monohydrate in its Synthetic Mixture. American Journal of PharmTech Research. 2018, 8(2): 296-306. doi: 10.46624/ajptr.2018.v8.i2.024

[16]. Rahman N, Azmi SNH, Wu HF. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accreditation and Quality Assurance. 2006, 11(1-2): 69-74. doi: 10.1007/s00769-006-0095-y

[17]. Impurities in New Drug Substances Q3A (R2). Available online: http//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf (accessed on 7 October 2023).

[18]. Guidance for Industry ANDAs: Impurities in Drug Products. Available online: https://www.fda.gov/files/drugs/published/ANDAs--Impurities-in-Drug-Products.pdf (accessed on 7 October 2023).

[19]. USP General Chapter <1225> Validation of Compendial Procedures. Available online: https://www.drugfuture.com/Pharmacopoeia/usp35/PDF/0877-0882%20%5B1225%5D%20VALIDATION%20OF%20COMPENDIAL%20PROCEDURES.pdf (accessed on 7 October 2023).

[20]. Validation of Analytical Procedures: Text and Methodology. ICH guideline Q2(R1). Available online: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf (accessed on 7 October 2023).

[21]. Methods, Method Verification, and Validation (ORA-LAB.5.4.5).

[22]. Available online: https://www.fda.gov/media/73920/download (accessed on 7 October 2023).